We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

11 hedge funds and large institutions have $277K invested in Phio Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

182% more capital invested

Capital invested by funds: $98.3K → $277K (+$179K)

83% more funds holding

Funds holding: 6 → 11 (+5)

5.59% more ownership

Funds ownership: 3.31% → 8.9% (+5.6%)

Holders
11
Holders Change
+5
Holders Change %
+83.33%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$121K
2
HF
HRT Financial
New York
+$115K
3
VF
Virtu Financial
New York
+$111K
4
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$35.3K
5
Morgan Stanley
Morgan Stanley
New York
+$16.1K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$86.7K
2
NA
Nordwand Advisors
Pennsylvania
-$1.73K

PHIO Hedge Fund Activity: Q4 2024 in Review

11 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2024, worth a combined $277K — up 182% from $98.3K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PHIO positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $121K. The largest seller was Sabby Management, exiting entirely with an estimated $86.7K sold.

  • 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2024, up from 6 in Q3 2024.
  • Funds reported $277K of Phio Pharmaceuticals stock for Q4 2024, up 182% quarter-over-quarter.
  • 7 funds opened new Phio Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of +5 holders.
  • The largest Phio Pharmaceuticals buyer in Q4 2024 was Citadel Advisors, an estimated $121K added.
  • The largest Phio Pharmaceuticals seller in Q4 2024 was Sabby Management, an estimated $86.7K sold.

Based on aggregated 13F filings for Q4 2024.